Intratect

Human normal immunoglobulin, the active ingredient in Intratect, is an immunoglobulin (IVIG) presented as a solution for injection for intravenous use. It treats primary and secondary immunodeficiency diseases, idiopathic thrombocytopenic purpura, Kawasaki disease, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.

GNH USA supplies Intratect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Intratect is an intravenous immunoglobulin used to replace deficient antibodies and modulate immune activity in several disorders.

Primary immunodeficiency diseases: provides IgG replacement to reduce infection frequency. Secondary immunodeficiency (e.g., chemotherapy): restores antibody levels to protect against opportunistic infections. Idiopathic thrombocytopenic purpura (ITP): raises platelet count by modulating autoimmune destruction. Kawasaki disease: reduces systemic inflammation and lowers risk of coronary artery complications. Chronic inflammatory demyelinating polyneuropathy (CIDP): improves muscle strength and functional ability. Multifocal motor neuropathy: alleviates motor weakness and enhances daily function.

Intratect may cause a range of adverse reactions, most of which are related to the infusion process or immune modulation.

Common Side Effects: - Headache - Fever or chills - Fatigue or malaise - Nausea or vomiting - Mild infusion‑related reactions (e.g., flushing, itching) - Transient blood pressure changes

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction - Thromboembolic events (e.g., deep vein thrombosis, stroke) - Acute renal dysfunction or failure - Aseptic meningitis - Hemolysis - Severe thrombocytopenia

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

Assess IgG levels: determine baseline immunoglobulin status before each infusion. Monitor infusion reactions: observe patients closely during and after administration. Adjust infusion rate: slow the rate if adverse symptoms develop. Avoid use in patients with known IgA deficiency who have anti‑IgA antibodies. Evaluate renal function: especially in patients with pre‑existing kidney disease or receiving nephrotoxic drugs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intratect can interact with several medications and biologics, influencing safety or efficacy.

Major Interactions (Avoid): - Live vaccines: may cause uncontrolled infection. - High‑dose aspirin or other NSAIDs: increase bleeding risk. - Concurrent immunoglobulin products: may lead to excess IgG load.

Moderate Interactions (Monitor Closely): - Corticosteroids: heightened infection susceptibility. - Diuretics: potential for renal impairment during infusion.